DURHAM, N.C. — French life sciences firm bioMerieux is selling its operation in Durham as part of a larger transaction with Ireland-based Trinity Biotech.

Trinity said operations in Durham would be transferred to Ireland. Biomerieux operations in St. Louis that are also part of the deal will be transferred to a site in New York.

bioMerieux had originally acquired the Durham facility in Treyburn Corporate Park from Organon Teknika in 2001, according to the Triangle Business Journal.

Trinity is paying bioMerieux as much as $51.9 million for its Coagulation product line . It includes diagnostic tests that are manufactured primarily in Durham as well as automated instruments that are made in St. Louis, Trinity said in a statement.

“As part of the transition, Trinity will transfer production of the diagnostic tests and instruments from bioMérieux’s facilities in North Carolina to Dublin and from St Louis to Jamestown, New York respectively,” the company said in a statement.

bioMerieux: www.biomeriux.com